Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.

Author:

Besse Benjamin1,Solomon Benjamin J.2,Felip Enriqueta3,Bauer Todd Michael4,Ou Sai-Hong Ignatius5,Soo Ross A.6,Camidge D Ross7,Chiari Rita8,Gadgeel Shirish M.9,Riely Gregory J.10,Tan Eng Huat11,Hayashi Hidetoshi12,Mazieres Julien13,Thurm Holger C.14,Martini Jean-Francois14,Abbattista Antonello15,Peltz Gerson16,Clancy Jill S.17,Shaw Alice Tsang18

Affiliation:

1. Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France;

2. Peter MacCallum Cancer Centre, Melbourne, Australia;

3. Vall d’Hebron Institute of Oncology, Barcelona, Spain;

4. Sarah Cannon Cancer Research Institute/Tennessee Oncology, Nashville, TN;

5. University of California Irvine School of Medicine, Irvine, CA;

6. National University Hospital Singapore, Singapore, Singapore;

7. University of Colorado, Aurora, CO;

8. Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy;

9. University of Michigan, Ann Arbor, MI;

10. Memorial Sloan Kettering Cancer Center, New York, NY;

11. National Cancer Center, Singapore, Singapore;

12. Kindai University Faculty of Medicine, Osaka, Japan;

13. Toulouse University Hospital, Université Paul Sabatier, Toulouse, France;

14. Pfizer Oncology, La Jolla, CA;

15. Pfizer Oncology, Milan, Italy;

16. Pfizer Oncology, Groton, CT;

17. Inventiv Clinical, Princeton, NJ;

18. Massachusetts General Hospital Cancer Center, Boston, MA;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3